Updated:
BriaCell Therapeutics Corp.
Developing Novel Therapies to Destroy Cancer | BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp.
Developing Novel Therapies to Destroy Cancer | BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
—
Corporate office
—
Sector focus
Frequently asked questions
Is BriaCell structured as an asset manager or a biotechnology company?
BriaCell is a clinical-stage biotechnology company, not an asset manager. It is classified here because it operates in the public markets and manages capital for drug development, but its primary mission is therapeutic innovation, not investment.
What stage of development is BriaCell's lead drug candidate in?
Bria-IMT, the lead candidate, is in Phase III clinical trials for breast cancer. The company has reported data from earlier-phase studies, including a Phase II combination study with immune checkpoint inhibitors (per company press release, 2023).
How does BriaCell fund its operations?
BriaCell funds its operations through public equity offerings, including at-the-market offerings and private placements. As a pre-revenue company, it relies on capital markets for financing.
Does BriaCell have any approved products?
No. BriaCell has not received regulatory approval for any of its drug candidates. All candidates remain in clinical trials or preclinical development.
What is BriaCell's regulatory status?
BriaCell is a public company listed on the Nasdaq and TSX under the ticker BCTX. It is subject to SEC and Canadian securities regulatory requirements.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: